Lu Sheng-Ye, Wen-Jing Li, Lou Rui, Ma Rui, Zhu Ji-Hong, Jiang Hao
Peking University Institute of Hematology, Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Department of Emergency, Peking University People's Hospital, Beijing, China.
Leuk Res Rep. 2021 Jul 14;16:100258. doi: 10.1016/j.lrr.2021.100258. eCollection 2021.
cute promyelocytic leukemia (APL) is a highly curable hematology malignancy. The major factor influence prognosis of APL is early deaths (ED) during the course of induction therapy, especially in high-risk APL. Therefore, effective reduction of white blood cells and correction of coagulation abnormalities are the key points of treatment for high-risk APL. Due to COVID19 pandemic in China since Jan 2020, some patients with hematologic malignancies suspected of COVID-19 infection had been isolated and traditional intravenous chemotherapy drugs is not available in isolated wards. We had explored a regimen of an oral etoposide to reduce the tumor burden for high-risk APL and dual induction with retinoic acid (ATRA) and oral arsenic realgar-Indigo nautralis formula (RIF), and finally two cases of high-risk APL patients received complete remission in one month. It is indicated that pure oral induction regimen: oral etoposide, ATRA and RIF provides a novel therapy in outpatient clinics.
急性早幼粒细胞白血病（APL）是一种高度可治愈的血液系统恶性肿瘤。影响APL预后的主要因素是诱导治疗过程中的早期死亡（ED），尤其是在高危APL中。因此，有效降低白细胞和纠正凝血异常是高危APL治疗的关键。自2020年1月中国爆发新型冠状病毒肺炎疫情以来，一些疑似感染新型冠状病毒肺炎的血液系统恶性肿瘤患者被隔离，隔离病房无法使用传统的静脉化疗药物。我们探索了一种口服依托泊苷方案以减轻高危APL的肿瘤负荷，并与维甲酸（ATRA）和口服砷剂雄黄-靛玉红配方（RIF）进行双重诱导，最终2例高危APL患者在1个月内获得完全缓解。这表明单纯口服诱导方案：口服依托泊苷、ATRA和RIF为门诊治疗提供了一种新的治疗方法。
